357 related articles for article (PubMed ID: 20971817)
1. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d'Or (Burgundy, France).
Maynadié M; Girodon F; Manivet-Janoray I; Mounier M; Mugneret F; Bailly F; Favre B; Caillot D; Petrella T; Flesch M; Carli PM
Haematologica; 2011 Jan; 96(1):55-61. PubMed ID: 20971817
[TBL] [Abstract][Full Text] [Related]
2. [Establishing a registry of malignant hemopathies in Côte-d'Or. Preliminary results].
Carli PM; Milan C; Lorenzini JL; Devilliers E; Turc C; Cortet P; Bonhomme J
Nouv Rev Fr Hematol (1978); 1983; 25(5):329-35. PubMed ID: 6657484
[TBL] [Abstract][Full Text] [Related]
3. [Haematological malignancies: incidence in Basse-Normandie, France, for 1997-2004].
Troussard X; Duchenet V; Cornet E; Mouchel D; Malet M; Collignon A
Rev Epidemiol Sante Publique; 2009 Jun; 57(3):151-8. PubMed ID: 19375876
[TBL] [Abstract][Full Text] [Related]
4. Myeloproliferative disorders in the department of Côte d'Or between 1980 and 1986.
Heudes D; Carli PM; Bailly F; Milan C; Mugneret F; Petrella T
Nouv Rev Fr Hematol (1978); 1989; 31(5):375-8. PubMed ID: 2587208
[TBL] [Abstract][Full Text] [Related]
5. Incidence and Bayesian Mapping of Myeloid Hematologic Malignancies in Sardinia, Italy.
Broccia G; Carter J; Ozsin-Ozler C; De Matteis S; Cocco P
Cancer Control; 2023; 30():10732748231202906. PubMed ID: 37877513
[TBL] [Abstract][Full Text] [Related]
6. Incidence, survival and prevalence of myeloid malignancies in Europe.
Visser O; Trama A; Maynadié M; Stiller C; Marcos-Gragera R; De Angelis R; Mallone S; Tereanu C; Allemani C; Ricardi U; Schouten HC;
Eur J Cancer; 2012 Nov; 48(17):3257-66. PubMed ID: 22770878
[TBL] [Abstract][Full Text] [Related]
7. Incidence of myeloid neoplasms in Spain (2002-2013): a population-based study of the Spanish network of cancer registries.
Solans M; Sanvisens A; Ameijide A; Merino S; Rojas D; Alemán A; Banqueri E; Chico M; Marcos AI; de Castro V; Gil L; de Munain AL; Puigdemont M; Sánchez MJ; Perucha J; Ruiz-Armengol P; Chirlaque MD; Guevara M; Carulla M; Marcos-Gragera R
Sci Rep; 2022 Jan; 12(1):323. PubMed ID: 35013373
[TBL] [Abstract][Full Text] [Related]
8. Therapy-related myeloid neoplasms following treatment with radioiodine.
Schroeder T; Kuendgen A; Kayser S; Kröger N; Braulke F; Platzbecker U; Klärner V; Zohren F; Haase D; Stadler M; Schlenk R; Czibere AG; Bruns I; Fenk R; Gattermann N; Haas R; Kobbe G; Germing U
Haematologica; 2012 Feb; 97(2):206-12. PubMed ID: 21993688
[TBL] [Abstract][Full Text] [Related]
9. Incidence of hematopoietic malignancies in a well-defined population in France.
Carli PM; Milan C; Lorenzini JL; Guy H; Michiels R
Oncology; 1986; 43(6):354-7. PubMed ID: 3808567
[TBL] [Abstract][Full Text] [Related]
10. Is survival in myeloid malignancies really improving? A retrospective 15-year population-based study.
Osca-Gelis G; Puig-Vives M; Saez M; Gallardo D; Lloveras N; Guàrdia R; Marcos-Gragera R
Leuk Lymphoma; 2015 Apr; 56(4):896-902. PubMed ID: 25058372
[TBL] [Abstract][Full Text] [Related]
11. Haematopoietic malignancies in Côte d'Or (France): a population based study.
Carli PM; Milan C; Lange A; Devilliers E; Guy H; Faivre J
Br J Cancer; 1986 Jun; 53(6):811-5. PubMed ID: 3718834
[TBL] [Abstract][Full Text] [Related]
12. Survival of European patients diagnosed with myeloid malignancies: a HAEMACARE study.
Maynadié M; De Angelis R; Marcos-Gragera R; Visser O; Allemani C; Tereanu C; Capocaccia R; Giacomin A; Lutz JM; Martos C; Sankila R; Johannesen TB; Simonetti A; Sant M;
Haematologica; 2013 Feb; 98(2):230-8. PubMed ID: 22983589
[TBL] [Abstract][Full Text] [Related]
13. Incidence of myeloid malignancies by subtype in Hong Kong and comparisons with Asian and white men and women in the United States.
Bassig BA; Hu W; Morton LM; Ji BT; Xu J; Linet MS; Kwong YL; Rothman N; Wong KF; Lan Q
Leuk Lymphoma; 2022 Aug; 63(8):1917-1924. PubMed ID: 35412943
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study.
Granfeldt Østgård LS; Medeiros BC; Sengeløv H; Nørgaard M; Andersen MK; Dufva IH; Friis LS; Kjeldsen E; Marcher CW; Preiss B; Severinsen M; Nørgaard JM
J Clin Oncol; 2015 Nov; 33(31):3641-9. PubMed ID: 26304885
[TBL] [Abstract][Full Text] [Related]
15. Coverage and accuracy of myeloproliferative and myelodysplastic neoplasms in the Finnish Cancer Registry.
Leinonen MK; Rantanen M; Pitkäniemi J; Malila N
Acta Oncol; 2016 Jun; 55(6):782-6. PubMed ID: 26767306
[TBL] [Abstract][Full Text] [Related]
16. Underreporting of myeloid malignancies by United States cancer registries.
Craig BM; Rollison DE; List AF; Cogle CR
Cancer Epidemiol Biomarkers Prev; 2012 Mar; 21(3):474-81. PubMed ID: 22237987
[TBL] [Abstract][Full Text] [Related]
17. The importance of evaluating specific myeloid malignancies in epidemiological studies of environmental carcinogens.
Mundt KA; Dell LD; Boffetta P; Beckett EM; Lynch HN; Desai VJ; Lin CK; Thompson WJ
BMC Cancer; 2021 Mar; 21(1):227. PubMed ID: 33676443
[TBL] [Abstract][Full Text] [Related]
18. Increased risk of acute myeloid leukemias and myelodysplastic syndromes in patients who received thiopurine treatment for inflammatory bowel disease.
Lopez A; Mounier M; Bouvier AM; Carrat F; Maynadié M; Beaugerie L; Peyrin-Biroulet L;
Clin Gastroenterol Hepatol; 2014 Aug; 12(8):1324-9. PubMed ID: 24582568
[TBL] [Abstract][Full Text] [Related]
19. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8.
Koh Y; Kim I; Bae JY; Song EY; Kim HK; Yoon SS; Lee DS; Park SS; Park MH; Park S; Kim BK
Jpn J Clin Oncol; 2010 Nov; 40(11):1037-45. PubMed ID: 20587614
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of polycythemia vera in Cte d'Or (Burgundy).
Carli PM
Nouv Rev Fr Hematol (1978); 1994 Apr; 36(2):147-9. PubMed ID: 8036130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
